Thermo Fisher Scientific Blinatumomab Recombinant Mouse Monoclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / scFv, kappa

Expression System

CHO cells

Class

Recombinant Monoclonal

Type

Antibody

Immunogen

Human CD19/CD3E

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1.42 mg/mL

Purification

Metal-chelate chromatography

Storage buffer

30mM histidine, pH 5.8, with 10% sucrose, 0.02% Tween 80

Contains

no preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2910872

Product Specific Information

Endotoxin level < 0.01EU/µg by LAL method

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Target Information

Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto™. Blinatumomab was approved in December 2014 under the FDA`s accelerated approval program, which allows approval of a pharmaceutical to treat a serious or life-threatening disease based on clinical data showing the pharmaceutical has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.